サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514026

希少疾病用医薬品の世界市場

Orphan Drugs

出版日
ページ情報
英文 261 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
希少疾病用医薬品の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 261 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

希少疾病用医薬品の世界市場は2030年までに9,590億米ドルに達する見込み

2023年に3,617億米ドルと推定された希少疾病用医薬品の世界市場は、2030年には9,590億米ドルに達し、分析期間2023-2030年のCAGRは14.9%で成長すると予測されます。本レポートで分析したセグメントの1つである生物製剤は、CAGR 15.5%を記録し、分析期間終了時には6,123億米ドルに達すると予測されます。非生物学的製剤タイプのセグメントは、分析期間中CAGR 14.0％で成長すると推定されます。

米国市場は992億米ドル、中国はCAGR 14.1％で成長すると予測

米国の希少疾病用医薬品市場は2023年に992億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1,455億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは14.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.2%と12.4%と予測されています。欧州では、ドイツがCAGR 10.7%で成長すると予測されています。

世界の希少疾病用医薬品市場- 主要動向と促進要因のまとめ

アンメット・メディカル・ニーズへの対応に不可欠なアンメット・キーワードは、特に、開発コストが高く患者数が限られているため従来の市場開拓ではカバーできなかった希少疾患をターゲットとしています。これらの医薬品は、潜在的な収益が数,000万米ドルにも達する巨額の投資を正当化できないほど希少な疾患を対象として設計されており、分子発見から市場承認まで10年以上かかることが一般的です。このような課題にもかかわらず、希少疾病用医薬品は公衆衛生において重要な役割を担っており、多くの場合、治療の唯一の希望を提供しています。また、これらの医薬品は、一般的な疾患に対する既存の治療法を再利用し、より稀な適応症に拡大したものである可能性もあり、治療範囲と有用性を高めています。

希少疾病用医薬品の開発と支援は、1983年に米国で導入された希少疾病用医薬品法（Orphan Drug Act）をはじめとする法的枠組みによって大きく形成されてきました。この法律は、世界的に同様の政策とともに、税額控除、手数料の減免、市場独占権の延長など、希少疾患の治療開発を刺激するさまざまなインセンティブを提供しています。これらの疾患は、人口のごく一部、通常2000人に1人以下の割合で罹患し、世界中で数百万人に影響を与える膨大な疾患の代表です。この法的支援は、希少疾病用医薬品の開発を経済的に実行可能なものにし、製薬会社が通常であればROIの見込みが乏しいために避けるであろう研究分野に投資することを奨励することを目的としています。

将来を見据えて、希少疾病用医薬品の領域は、先端技術の統合が進み、規制状況が変化するにつれて拡大していくでしょう。遺伝子研究とバイオテクノロジーの進歩により、希少疾患の分子レベルでの特定と理解が飛躍的に進み、標的治療の開発が容易になった。個別化医療に向けた動きは、個人の遺伝子プロファイルに合わせた精密治療の限界を押し広げ続け、患者の転帰を大幅に改善しています。さらに、FDAやEMAといった機関が提供する規制上の優遇措置や迅速な承認プロセスは、希少疾病用医薬品の開発を促進する上で極めて重要です。共同研究イニシアティブや革新的な資金提供モデルも極めて重要であり、経済的負担を軽減し、より迅速な研究開発を促進します。希少疾病用医薬品の需要が高まり、この重要なヘルスケア分野における継続的な技術革新と支援の重要性が強調されています。

調査対象企業の例（全18件）

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corp.,
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Serono SA
  • Novartis AG
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sanofi SA
  • Shire Plc.
  • Vertex Pharmaceuticals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-7443

Global Orphan Drugs Market to Reach US$959.0 Billion by 2030

The global market for Orphan Drugs estimated at US$361.7 Billion in the year 2023, is expected to reach US$959.0 Billion by 2030, growing at a CAGR of 14.9% over the analysis period 2023-2030. Biologics Drug Type, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$612.3 Billion by the end of the analysis period. Growth in the Non-Biologics Drug Type segment is estimated at 14.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$99.2 Billion While China is Forecast to Grow at 14.1% CAGR

The Orphan Drugs market in the U.S. is estimated at US$99.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$145.5 Billion by the year 2030 trailing a CAGR of 14.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 12.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

Global Orphan Drugs Market - Key Trends and Drivers Summarized

Orphan drugs are vital in addressing unmet medical needs, specifically targeting rare diseases that traditional market incentives fail to cover due to high development costs and limited patient populations. These drugs are designed for conditions so rare that the potential revenue does not typically justify the enormous investment required, which can reach tens of millions and involve a decade-long journey from molecule discovery to market approval. Despite these challenges, orphan drugs play a critical role in public health, offering the only hope for treatment in many cases. These drugs may also be repurposed versions of existing treatments for common diseases, broadened to cover rarer indications, thus enhancing their therapeutic scope and utility.

The development and support for orphan drugs have been significantly shaped by legislative frameworks, notably the Orphan Drug Act introduced in the United States in 1983. This act, along with similar policies globally, provides various incentives such as tax credits, reduced fees, and extended market exclusivity to stimulate the development of treatments for rare diseases. These diseases affect a tiny fraction of the population, typically fewer than one person per 2000, representing a vast array of conditions that impact millions worldwide. The legislative support aims to make the development of orphan drugs economically viable and encourages pharmaceutical companies to invest in research areas they would likely avoid due to poor ROI prospects under normal circumstances.

Looking to the future, the realm of orphan drugs is set to expand with the growing integration of advanced technologies and shifting regulatory landscapes. Advances in genetic research and biotechnology have dramatically enhanced the identification and understanding of rare diseases at a molecular level, facilitating the development of targeted treatments. The movement towards personalized medicine continues to push the boundaries of precision therapies, tailored to individual genetic profiles, significantly improving patient outcomes. Furthermore, regulatory incentives and fast-track approval processes provided by entities such as the FDA and EMA are crucial in encouraging the development of orphan drugs. Collaborative research initiatives and innovative funding models are also pivotal, reducing the financial burden and fostering faster drug development. As awareness and advocacy grow, so does the support for addressing the unique challenges posed by rare diseases, thereby driving the demand for orphan drugs and underlining the importance of continued innovation and support in this crucial healthcare sector.

Select Competitors (Total 18 Featured) -

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corp.,
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Serono SA
  • Novartis AG
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sanofi SA
  • Shire Plc.
  • Vertex Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Orphan Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Rare Diseases
    • Growth of Biopharmaceutical Industry
    • Advancements in Genetic and Molecular Research
    • Rising Adoption of Personalized Medicine
    • Impact of COVID-19 Pandemic on Orphan Drug Development
    • Government Regulations and Incentives for Orphan Drugs
    • Expansion of Orphan Drug Applications in Various Therapeutic Areas
    • Development of Novel Drug Delivery Systems for Orphan Drugs
    • Consumer Preferences for Innovative and Effective Treatments
    • Role of Orphan Drugs in Enhancing Patient Outcomes and Quality of Life
    • Market Penetration of Orphan Drugs in Developing Regions
    • Influence of Technological Innovations on Orphan Drug Development
    • Growth of Orphan Drugs in Oncology and Rare Genetic Disorders
    • Emerging Markets and Growth Opportunities in Developing Regions
    • Future Trends and Innovations in Orphan Drug Research and Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • CHINA
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2024 & 2030

IV. COMPETITION